-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Society News
-
COCOON Regimen Demonstrates Improvement in Dermatologic Toxicities
Dr. Nicolas Girard recently presented data that shows prophylactic treatment with oral and topical antibiotics and ceramide-based moisturizer significantly reduced adverse skin events.
-
Savolitinib Plus Osimertinib Offers Hope for Addressing Resistance, Progression
Dr. Myung-Ju Ahn said recent data from SAVANNAH show the combination produced a meaningful and durable response in patients whose cancer progressed after osimertinib.
-
Final MARIPOSA Analysis Confirms OS Improvement Versus Osimertinib Monotherapy
Drs. Chih-Hsin Yang and Pérol reviewed the latest findings and key takeaways during a presentation at the European Lung Cancer Congress.
-
Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award
During his award lecture at the European Lung Cancer Congress, Dr. Kerr said lung cancer treatment has benefited from the bridging of the historical divide between pathology and medical oncology.
-
Foritinib Gains Momentum in China for ALK-positive NSCLC
China’s NMPA accepts a marketing authorization application for foritinib following interim results from the phase III REMARK trial.
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
Anti-obesity medications could theoretically reduce the absorption of oral TKIs, particularly in cases of lipophilicity, where therapeutic agents have a strong dependence on dietary fat for adequate dissolution.
-
Zipalertinib Meets Primary Endpoint in Phase 2b Trial
The drug’s developers have said the data show a positive overall response rate in previously treated patients with NSCLC with EGFR exon 20 insertion mutations.
-
Will Bispecific Antibodies Replace PD-(L)1 Targeted Agents?
Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies.
-
Debate Leaves Audience Unconvinced that KRAS Inhibitors Deserve Promotion to First-Line Treatment
While Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard of care.
-
Updated Data Show Median OS of 16.9 months in Patients with Advanced NSCLC Treated with THIO
Though the study is small, the sponsor says results are promising for the first-in-class telomere-targeting agent.